The primary goal of this study is to gather efficacy data concerning the progression-free
survival rate with electromagnetic fields plus Regorafenib when compared to historical data
with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular
carcinoma who have received any first line systemic therapy either standard of care Sorafenib
or Lenvatinib or any experimental therapy. Patients who have received any treatment that
includes either electromagnetic fields or Regorafenib will be excluded.
Primary Objective: To estimate progression-free survival rates.
- To obtain information concerning the feasibility of administration of the proposed
treatment, including patient participation in trials using the proposed treatment.
- To evaluate safety and tolerability in this patient population.
- To evaluate the effect on levels of alpha-fetoprotein.
- Biopsy-proven hepatocellular carcinoma is locally advanced or metastatic. OR
- Patients without biopsy confirmation are also eligible if they meet the following:
- Radiologic diagnosis of hepatocellular carcinoma as per the American Association for
the Study of Liver Diseases (AASLD) guidelines:
- liver cirrhosis AND
- a liver mass confirmed by blinded independent central review that shows arterial phase
hyperenhancement on triphasic CT or MRI, AND EITHER:
- Is ≥20 mm with either non-peripheral portal washout or an enhancing capsule
- OR is 10-19 mm with non-peripheral portal venous washout AND an enhancing capsule.
- Patient must have been treated with at least one standard systemic treatment modality
for advanced hepatocellular carcinoma such as sorafenib, lenvatanib, atezolizumab plus
bevacizumab, or another approved or experimental systemic therapy prior to study
- Measurable disease according to RECIST version 1.1 and mRECIST for hepatocellular
- At least one target lesion should not have previously received any local therapy, such
as surgery, radiation therapy, hepatic arterial embolization, transarterial
chemoembolization (TACE), hepatic arterial infusion, radio-frequency ablation,
percutaneous ethanol injection or cryoablation, unless it has subsequently progressed
by 20% or more according to RECIST version 1.1 and mRECIST for hepatocellular
- Patients with Child's Pugh A (at time of enrollment), with compensated cirrhosis, as
defined by the parameters contained in the Child Pugh Calculator found in Appendix E.
- Performance status Eastern Cooperative Oncology Group (ECOG) 0-2
- Absence of medical or psychiatric contraindication which, in the opinion of the
treating Investigator, would make the patient's participation in this trial
- Patient must not have curative treatment options, including surgery or radiofrequency
- Any extra-hepatic metastases, including treated central nervous system metastases but
patients cannot have leptomeningeal disease.
- At least 2 weeks must have elapsed since administration of any anti-cancer treatment.
- Other anti-cancer treatments are not permitted during this study, including
alternative medicine and herbal therapies.
- Patients must be 18+ years old and must be able to understand and sign an informed
- Patient must agree to be followed up according to the study protocol.
- Known leptomeningeal disease.
- Fibro lamellar hepatocellular carcinoma.
- Patients who had surgical resection of the disease and who do not have measurable
- Patients with any of the following history within the 12 months prior to study drug
administration: severe/unstable angina, myocardial infarction, coronary artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident, including
transient ischemic attack, or pulmonary embolism.
- Pregnant or breastfeeding women.
- Patients diagnosed with another type of cancer (excluding basal cell carcinoma) whose
cancer diagnosed previously is not in remission.
- Patients receiving calcium channel blockers and any agent blocking L-type or T-type
Voltage Gated Calcium Channels, e.g. amlodipoine, nifedipine, ethosuximide, etc. are
not allowed in the study unless their medical treatment is modified to exclude calcium
channel blockers prior to enrollment.
- Patients allergic or intolerant to Sorafenib.